169 related articles for article (PubMed ID: 28695347)
1. Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies.
Wilson SE; Graham DR; Wang W; Bruss JB; Castaneda-Ruiz B
Infect Dis Ther; 2017 Sep; 6(3):413-422. PubMed ID: 28695347
[TBL] [Abstract][Full Text] [Related]
2. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.
McKinnell JA; Corman S; Patel D; Leung GH; Gordon LM; Lodise TP
Clin Ther; 2018 Mar; 40(3):406-414.e2. PubMed ID: 29454592
[TBL] [Abstract][Full Text] [Related]
3. Chemical Stability of Telavancin in Elastomeric Pumps.
Sand P; Aladeen T; Kirkegaard P; LaChance D; Slover C
Curr Ther Res Clin Exp; 2015 Dec; 77():99-104. PubMed ID: 26649079
[TBL] [Abstract][Full Text] [Related]
4. Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials.
Niederman MS; Lee PC; Barriere SL; Barnes CN; Castaneda-Ruiz B
Infect Dis Ther; 2019 Sep; 8(3):445-452. PubMed ID: 31372837
[TBL] [Abstract][Full Text] [Related]
5. A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).
Dunbar LM; Tang DM; Manausa RM
Ther Clin Risk Manag; 2008 Feb; 4(1):235-44. PubMed ID: 18728713
[TBL] [Abstract][Full Text] [Related]
6. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.
Das B; Sarkar C; Das D; Gupta A; Kalra A; Sahni S
Ther Adv Infect Dis; 2017 Mar; 4(2):49-73. PubMed ID: 28634536
[TBL] [Abstract][Full Text] [Related]
7. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Barriere SL
Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
[TBL] [Abstract][Full Text] [Related]
8. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
Lacy MK; Stryjewski ME; Wang W; Hardin TC; Nogid B; Luke DR; Shorr AF; Corey GR; Barriere SL
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S87-93. PubMed ID: 26316562
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.
Torres A; Rubinstein E; Corey GR; Stryjewski ME; Barriere SL
J Antimicrob Chemother; 2014 Apr; 69(4):1119-26. PubMed ID: 24398339
[TBL] [Abstract][Full Text] [Related]
10. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Corey GR; Rubinstein E; Stryjewski ME; Bassetti M; Barriere SL
Clin Infect Dis; 2015 Mar; 60(5):787-96. PubMed ID: 25472944
[TBL] [Abstract][Full Text] [Related]
11. Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
Liapikou A; Dimakou K; Toumbis M
Ther Adv Respir Dis; 2016 Aug; 10(4):368-78. PubMed ID: 27340253
[TBL] [Abstract][Full Text] [Related]
12. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.
Wilson SE; O'Riordan W; Hopkins A; Friedland HD; Barriere SL; Kitt MM;
Am J Surg; 2009 Jun; 197(6):791-6. PubMed ID: 19095213
[TBL] [Abstract][Full Text] [Related]
13. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.
Barriere SL
Future Microbiol; 2010 Dec; 5(12):1765-73. PubMed ID: 21080861
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia.
Rubinstein E; Stryjewski ME; Barriere SL
Infect Drug Resist; 2014; 7():129-35. PubMed ID: 24876786
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
Stryjewski ME; Barriere SL; O'Riordan W; Dunbar LM; Hopkins A; Genter FC; Corey GR
J Antimicrob Chemother; 2012 Jun; 67(6):1496-502. PubMed ID: 22416054
[TBL] [Abstract][Full Text] [Related]
16. Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).
Hooper CY; Smith WJ
Ther Clin Risk Manag; 2012; 8():131-7. PubMed ID: 22547931
[TBL] [Abstract][Full Text] [Related]
17. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
Scheinfeld N
J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
[TBL] [Abstract][Full Text] [Related]
18. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
[TBL] [Abstract][Full Text] [Related]
19. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.
Smart JI; Corey GR; Stryjewski ME; Wang W; Barriere SL
Infect Dis Ther; 2016 Dec; 5(4):535-544. PubMed ID: 27718118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
